The Treatment of Patients With Bone Health Issues
Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, on the treatment of patients with breast cancer with bone health issues.
Toxicities Associated With PI3K Inhibitors
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
The Role of Everolimus in Breast Cancer and the BOLERO Trials
Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the role of Afinitor (everolimus) in breast cancer and the BOLERO trials.
An Expanded Access Study of T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.